The US Food and Drug Administration (FDA) has granted fast track designation to LYT-200 for the treatment of acute myeloid leukemia (AML).
LYT-200 is a first-in-class anti-galectin-9 monoclonal antibody and is currently being evaluated in two phase 1/2 trials for the potential treatment of patients with AML, myelodysplastic syndromes, and other cancers.
“Fast Track designation from the FDA reinforces our belief in the potential for LYT-200 to address the urgent needs of AML patients,” a representative from PureTech Health, the developer of LYT-200, said in a press release from the company.
